Endothelial cell injury in cardiovascular surgery: The procoagulant response

Annals of Thoracic Surgery

Volumn 62, Issue 5, 1996, Pages 1549-1557

  Boyle, Edward M ^a   Verrier, Edward D ^a   Spiess, Bruce D ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLASMINOGEN ACTIVATOR; PROCOAGULANT; THROMBIN;

BLEEDING; BLOOD CLOTTING; CARDIOPULMONARY BYPASS; CARDIOVASCULAR SURGERY; CELL DAMAGE; FIBRINOLYSIS; HUMAN; INFLAMMATION; PRIORITY JOURNAL; REVIEW; THROMBOCYTOPENIA; VASCULAR ENDOTHELIUM;

EID: 0030297174     PISSN: 00034975     EISSN: None     Source Type: Journal    
DOI: 10.1016/0003-4975(96)00836-3     Document Type: Review

References (54)

1. 1. Subramaniam P, Skillington P, Tatoulis J. Heparin-rebound in the early postoperative phase following cardiopulmonary bypass. Aust N Z J Surg 1995;65:331-3.
2. 2. Ray MJ, Marsh NA, Hawson GA. Relationship of fibrinolysis and platelet function to bleeding after cardiopulmonary bypass. Blood Coagul Fibrinolysis 1994;5:679-85.
3. 3. Shainoff JR, Estafanous FG, Yared JP, et al. Low factor XIIIA levels are associated with increased blood loss after coronary artery bypass grafting. J Thorac Cardiovasc Surg 1994;108: 437-45.
4. 4. Spiess BD. The contribution of fibrinolysis to postbypass bleeding. J Cardiothorac Vasc Anesth 1991;5:13-7.
5. 5. Woodman RC, Harker LA. Bleeding complications associated with cardiopulmonary bypass. Blood 1990;76:1680-97.
6. 6. Ferrara A, MacArthur JD, Wright HK, et al. Hypothermia and acidosis worsen coagulopathy in the patient requiring massive transfusion. Am J Surg 1990;160:515-8.
7. 7. Ferraris VA, Ferraris SP. Limiting excessive postoperative blood transfusion after cardiac procedures. Tex Heart Inst J 1995;22:216-30.
8. 8. Moulton MJ, Creswell LL, Mackey ME, et al. Reexploration for bleeding is a risk factor for adverse outcomes after cardiac operations. J Thorac Cardiovasc Surg 1996;111: 1037-46.
9. 9. Ray MJ, Hawson GA, Just SJ, et al. Relationship of platelet aggregation to bleeding after cardiopulmonary bypass. Ann Thorac Surg 1994;57:981-6.
10. 10. Brister SJ, Ofosu FA, Buchanan MR. Thrombin generation during cardiac surgery: is heparin the ideal anticoagulant? Thromb Haemost 1993;70:259-62.
11. 11. Backmann F, McKenna R, Cole ER, Najafi H. The hemostatic mechanism after open-heart surgery. I. Studies on plasma coagulation factors and fibrinolysis in 512 patients after extracorporeal circulation. J Thorac Cardiovasc Surg 1975;70: 76-85.
12. 12. Santos MT, Valles J, Marcu-AJ, et al. Enhancement of platelet reactivity and modulation of eicosanoid production by intact erythrocytes. J Clin Invest 1991;87:571-80.
13. 13. Billiar TR. Nitric oxide: novel biology with clinical relevance. Ann Surg 1995;221:339-49.
14. 14. Davie EW, Fumikawa K, Kisiel W. The coagulation cascade: initiation, maintenance, and regulation. Biochemistry 1991; 30:10363-70.
15. 15. Nemerson Y. The tissue factor pathway of blood coagulation. Semin Hematol 1992;29:170-6.
16. 16. Luchtman-Jones L, Broze GT. The current status of coagulation. Ann Med 1995;27:47-52.
17. 17. Steed DL. Hemostasis and coagulation. In: Simmons RL, Steed DL, eds. Basic science review for surgeons. Philadelphia, 1992:30-7.
18. 18. Horrow JC. Management of coagulopathy associated with cardiopulmonary bypass. In: Gravlee GP, Davis RF, Utley JR, eds. Cardiopulmonary bypass: principles and practice. Baltimore: Williams and Wilkins, 1993:436-66.
19. 19. Parry GC, Mackman N. Transcriptional regulation of tissue factor expression in human endothelial cells. Arterioscler Thromb Vasc Biol 1995;15:612-21.
20. 20. Tijburg PNM, Ryan J, Stern DM, et al. Activation of the coagulation mechanism on tumor necrosis factor stimulated cultured endothelial cells and their extracellular matrix: the role of flow and factor IX/IXa. J Biol Chem 1991;266:12067-74.
21. 21. Dietrich W. Reducing thrombin formation during cardiopulmonary bypass: is there a benefit of the additional anticoagulant action of aprotinin? J Cardiovasc Pharm 1996;27(Suppl 1):S-50-7.
22. 22. Kappelmayer J, Bernabei A, Edmunds H, et al. Tissue factor is expressed on monocytes during simulated extracorporeal circulation. Circ Res 1993;72:1075-81.
23. 23. Boisclair MD, Lane DA, Philippou H, et al. Mechanisms of thrombin generation during surgery and cardiopulmonary bypass. Blood 1993;82:3350-7.
24. 24. Boldt J, Schindler E, Knothe C, et al. Does aprotinin influence endothelial-associated coagulation in cardiac surgery? J Cardiothorac Vasc Anesth 1994;8:527-31.
25. 25. German RC, Ziats NP, Rao AK, et al. Surface-bonded heparin fails to reduce thrombin formation during clinical cardiopulmonary bypass. J Thorac Cardiovasc Surg 1996;111: 1-12.
26. 26. Bevilacqua MP, Schleef RR, Gimbrone MA Jr, Loskutoff DJ. Regulation of the fibrinolytic system of cultured human vascular endothelium by interleukin 1. J Clin Invest 1986;78: 587-91.
27. 27. Bevilacqua MP, Pober JS, Majeau GR, et al. Recombinant tumor necrosis factor induces procoagulant activity in cultured human vascular endothelium: characterization and comparison with the actions of interleukin 1. Proc Natl Acad Sci USA 1986;83:4533-7.
28. 28. Mackman N, Brand K, Edgington T. Lipopolysaccharide-mediated transcriptional activation of the human tissue factor gene in THP-1 monocytic cells requires both activator protein 1 and nuclear factor kB binding sites. J Exp Med 1991;174:1517-26.
29. 29. Nawroth PP, Handley DA, Esmon CT, Stern DM. Interleukin 1 induces endothelial cell procoagulant while suppressing cell-surface anticoagulant activity. Proc Natl Acad Sci USA 1986;83:3460-4.
30. 30. Bauer KA, Ten CH, Barzegar S, et al. Tumor necrosis factor infusions have a procoagulant effect on the hemostatic mechanism of humans. Blood 1989;74:165-72.
31. 31. Altieri DC, Morrissey JH, Edgington TS. Adhesive receptor Mac-1 corrdinates the activation of factor X on stimulated cells of monocytic and myeloid differentiation: an alternative initiation of the coagulation protease cascade. Proc Natl Acad Sci USA 1988;85:7462-6.
32. 32. Rinder CS, Bohnert J, Rinder HM, et al. Platelet activation and aggregation during cardiopulmonary bypass. Anesthesiology 1991;75:388-93.
33. 33. Wegner RK, Lukasiewicz H, Mikuta BS, et al. Loss of platelet fibrinogen receptors during clinical cardiopulmonary bypass. J Thorac Cardiovasc Surg 1989;97:235-43.
34. 34. McEver RP, Beckstead JH, Moore KL, et al. GMP-140, a platelet alpha-granule membrane protein, is also synthesized by vascular endothelial cells and is localized in Weibel-Palade bodies. J Clin Invest 1989;84:92-9.
35. 35. Foreman KE, Vaporciyan AA, Bonish BK, et al. C5a-induced expression of P-selectin in endothelial cells. J Clin Invest 1994;94:1147-55.
36. 36. Spiess BD. Ischemia - a coagulation problem? J Cardiovasc Pharm 1996;27:S38-41.
37. 37. Weyrich AS, Ma XY, Lefer DJ, et al. In vivo neutralization of P-selectin protects feline heart and endothelium in myocardial ischemia and reperfusion injury. J Clin Invest 1993;91: 2620-9.
38. 38. Winn RK, Liggitt D, Vedder NB, et al. Anti-P-selectin monoclonal antibody attenuates reperfusion injury to the rabbit ear. J Clin Invest 1993;92:2042-7.
39. 39. Simpson PJ, Todd RF III, Fantone JC, et al. Reduction of experimental canine myocardial reperfusion injury by a monoclonal antibody (anti-Mo1, anti-CD11b) that inhibits leukocyte adhesion. J Clin Invest 1988;81:624-9.
40. 40. Lucore C. Regulation of fibrinolysis by vascular endothelium. Coron Artery Dis 1991;2:157-66.
41. 41. Greilich PE, Carr ME Jr, Carr SL, Chang AS. Reductions in platelet force development by cardiopulmonary bypass are associated with hemorrhage. Anesth Analg 1995;80:459-65.
42. 42. Gouin I, Lecompte T, Morel MC, et al. In vitro effect of plasmin on human platelet function in plasma. Inhibition of aggregation caused by fibrinogenolysis. Circulation 1991;85: 935-41.
43. 43. Hanss M, Collen D. Secretion of tissue-type plasminogen activator and plasminogen activator inhibitor by cultured human endothelial cells: modulation by thrombin, endotoxin, and histamine. J Lab Clin Med 1987;109:97-104.
44. 44. Tanaka K, Takao M, Yaka I, et al. Alterations in coagulation and fibrionlysis associated with cardiopulmonary bypass during open hert surgery. J Cardiothorac Anesth 1989;3: 181-8.
45. 45. Emeis JJ, Kooistra T. Interleukin 1 and lipopolysaccharide induce an inhibitor of tissue-type plasminogen activator in vivo and in cultured endothelial cells. J Exp Med 1986;163: 1260-6.
46. 46. Nachman RL, Hajjar KA, Silverstein RL, Dinarello CA. Interleukin 1 induces endothelial cell synthesis of plasminogen activator inhibitor. J Exp Med 1986;163:1595-600.
47. 47. Chandler WL, Fitch JC, Wall MH, et al. Individual variations in the fibrinolytic response during and after cardiopulmonary bypass. Thromb Haemost 1995;74:1293-7.
48. 48. Kestin AS, Valeri CR, Khuri SF, et al. The platelet function defect of cardiopulmonary bypass. Blood 1993;82:107-17.
49. 49. Mastroroberto P, Chello M, Zofrea S, Marchese AR. Suppressed fibrinolysis after administration of low-dose aprotinin: reduced level of plasmin-alpha2-plasmin inhibitor complexes and postoperative blood loss. Eur J Cardiothorac Surg 1995;9:143-5.
50. 50. Boldt J, Schindler E, Knothe C, et al. Does aprotinin influence endothelial-associated coagulation in cardiac surgery? J Cardiothorac Vasc Anesth 1994;8:527-31.
51. 51. Van Oeveren W, Harder MP, Roozendaal KJ, et al. Aprotinin protects platelets against the initial effect of cardiopulmonary bypass. J Thorac Cardiovasc Surg 1990;99:788-97.
52. 52. Moliterno DJ, Califf RM, Aguirre FV, et al. Effect of platelet glycoprotein IIb/IIIa integrin blockade on activated clotting time during percutaneous transluminal coronary angioplasty or directional atherectomy (the EPIC Trial). Am J Cardiol 1995;75:559-62.
53. 53. Edgington TS, Ruf W, Rehemtulla A, Mackman N. The molecular biology of initiation of coagulation by tissue factor. Curr Stud Hematol Blood Trans 1991;58:15-21.
54. 54. Johnson M, Haddix T, Pohlman T, Verrier ED. Hypothermia reversibly inhibits endothelial cell expression of E-selectin and tissue factor. J Card Surg 1995;10:428-35.